Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges

Liu, Caiyun; Shi, Mingchao; Zhu, Mingqin; Chu, Fengna; Jin, Taiyi; Zhu, Jian

doi:10.1016/j.autrev.2021.102921

Cited by 8 publications

(5 citation statements)

References 190 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the same study, none of the patients with MOGAD had similar autoantibodies. The Neuromyelitis Optica Study Group (NEMOS) 22 and Liu et al 23 also recommended testing for auto-antibodies in patients with suspected NMOSD.…”

Section: Discussionmentioning

confidence: 99%

“…Without a clear consensus for systematic anti-AQP4 antibody testing, we might consider testing to be modulated geographically or by the ethnicity of the considered populations. Indeed, the prevalence of NMOSD differs by racial populations—it is 1/1, in White compared to 3.5/1, in the population with Asian ancestry and in East Asians, and 1 /1, in Africans 1,23 . In multiethnic Singapore, the prevalence of NMOSD was 3.8/1, or 32.5% of 468 patients with CNS IDD 11 .…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, the prevalence of NMOSD differs by racial populationsit is 1/1, in White compared to 3.5/1, in the population with Asian ancestry and in East Asians, and 1 /1, in Africans. 1,23 In multiethnic Singapore, the prevalence of NMOSD was 3.8/1, or 32.5% of 468 patients with CNS IDD. 11 More specifically for optic neuritis, the seroprevalence of NMOSD also differs geographically and might be as high as 27% in Asians, compared to only 4% in non-Asians.…”

Section: Anti-aqp4 Antibody Testingmentioning

confidence: 99%

See 2 more Smart Citations

Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore

Foo

Yau

Singhal

et al. 2022

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: The Optic Neuritis Treatment Trial was a landmark study with implications worldwide. In the advent of antibody testing for neuromyelitis optica spectrum disease (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), emerging concepts, such as routine antibody testing and management, remain controversial, resulting mostly from studies in White populations. We evaluate the practice patterns of optic neuritis investigation and management by neuro-ophthalmologists and neurologists in Singapore. Design: 21-question online survey consisting of 4 clinical vignettes. Methods: The survey was sent to all Singapore Medical Council– registered ophthalmologists and neurologists who regularly manage patients with optic neuritis. Results: Forty-two recipients (17 formally trained neuro-ophthalmol-ogists [100% response rate] and 25 neurologists) responded. Participants opted for routine testing of anti–aquaporin-4 antibodies (88.1% in mild optic neuritis and 97.6% in severe optic neuritis). Anti-MOG antibodies were frequently obtained (76.2% in mild and 88.1% in severe optic neuritis). Plasmapheresis was rapidly initiated (85.7%) in cases of nonresponse to intravenous steroids, even before obtaining anti–aquaporin-4 or anti-MOG serology results. In both NMOSD and MOGAD, oral mycophenolate mofetil was the preferred option if chronic immunosuppression was necessary. Steroids were given for a longer duration and tapered more gradually than in idiopathic optic neuritis cases. Conclusions: Serological testing for NMOSD and MOGAD is considered as a routine procedure in cases of optic neuritis in Singapore, possibly due to local epidemiological features of these conditions. Chronic oral immunosuppression is preferred for the long term, but further research is necessary to establish the efficacy and cost-effectiveness of these practices.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Anti-aqp4 Antibody Testingmentioning

confidence: 99%

See 1 more Smart Citation

Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore

Foo

Yau

Singhal

et al. 2022

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…It is also required to detect MOG‐IgG in NMOSD patients without AQP4‐IgG to determine or exclude MOGAD. However, it is still difficult to correctly diagnose NMOSD without AQP4‐IgG/MOG‐IgG relying on the clinical and imaging manifestations so far 23 . This brings challenges to the diagnosis of NMOSD and need to be carefully differentiated from MS, MOGAD, and other demyelinating diseases in the CNS 2 …”

Section: Introductionmentioning

confidence: 99%

“…However, it is still difficult to correctly diagnose NMOSD without AQP4-IgG/MOG-IgG relying on the clinical and imaging manifestations so far. 23 This brings challenges to the diagnosis of NMOSD and need to be carefully differentiated from MS, MOGAD, and other demyelinating diseases in the CNS. 2 Majority of AQP4-IgG is produced in peripheral lymphoid tissues, so the levels of AQP4-IgG in serum are much higher than in CSF.…”

mentioning

confidence: 99%

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

et al. 2022

Self Cite

View full text Add to dashboard Cite

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory demyelinating disorder of the central nervous system (CNS), which is a severely disabling disorder leading to devastating sequelae or even death. Repeated acute attacks and the presence of aquaporin‐4 immunoglobulin G (AQP4‐IgG) antibody are the typical characteristics of NMOSD. Recently, the phase III trials of the newly developed biologicals therapies have shown their effectiveness and good tolerance to a certain extent when compared with the traditional therapy with the first‐ and second‐line drugs. However, there is still a lack of large sample, double‐blind, randomized, clinical studies to confirm their efficacy, safety, and tolerability. Especially, these drugs have no clear effect on NMOSD patients without AQP4‐IgG and refractory patients. Therefore, it is of strong demand to further conduct large sample, double‐blind, randomized, clinical trials, and novel therapeutic possibilities in NMOSD are discussed briefly here.

show abstract

An in-vitro evaluation of antifungal, anti-lungcancer (A549), and anti-hyperglycemic activities potential of Andrographis paniculata (Burm. f.) flower extract

Phuong,

Duy Tai,

Aloufi

et al. 2023

Environmental Research

View full text Add to dashboard Cite

Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges

Cited by 8 publications

References 190 publications

Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore

Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

An in-vitro evaluation of antifungal, anti-lungcancer (A549), and anti-hyperglycemic activities potential of Andrographis paniculata (Burm. f.) flower extract

Contact Info

Product

Resources

About